Valitor Presents Preclinical Data Demonstrating VLTR-559 Achieves Superior Durability and Sustained Anti-VEGF Activity with a Favorable Safety Profile as a Treatment for Wet AMD

Valito announced new preclinical data demonstrating that VLTR-559, a long-acting anti-VEGF biologic designed to enable twice-yearly dosing for the treatment of wet age-related macular degeneration (AMD), achieved its preclinical durability and safety targets compared with approved short-acting anti-VEGF therapies for wet AMD.